litlas
ログインアカウント作成

Kongming Wu

1999–2026 年に発表

251
論文数
32,685
被引用数
100
h 指数
239
i10 指数

被引用数

Kongming Wu の年別被引用数1976 年: 被引用 1 件1977 年: 被引用 1 件1996 年: 被引用 2 件2000 年: 被引用 1 件2001 年: 被引用 2 件2002 年: 被引用 7 件2003 年: 被引用 4 件2004 年: 被引用 38 件2005 年: 被引用 39 件2006 年: 被引用 51 件2007 年: 被引用 40 件2008 年: 被引用 58 件2009 年: 被引用 62 件2010 年: 被引用 96 件2011 年: 被引用 90 件2012 年: 被引用 94 件2013 年: 被引用 119 件2014 年: 被引用 84 件2015 年: 被引用 107 件2016 年: 被引用 123 件2017 年: 被引用 117 件2018 年: 被引用 168 件2019 年: 被引用 677 件2020 年: 被引用 1,011 件2021 年: 被引用 1,473 件2022 年: 被引用 1,490 件2023 年: 被引用 1,513 件2024 年: 被引用 2,645 件2025 年: 被引用 1,502 件2026 年: 被引用 67 件1978〜1995 年は被引用が無いため表示していません1997〜1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 4,624 件、この内訳の 35.3%アメリカ合衆国: 引用元論文 2,199 件、この内訳の 16.8%イギリス: 引用元論文 428 件、この内訳の 3.3%インド: 引用元論文 415 件、この内訳の 3.2%ドイツ: 引用元論文 405 件、この内訳の 3.1%イタリア: 引用元論文 405 件、この内訳の 3.1%韓国: 引用元論文 282 件、この内訳の 2.2%フランス: 引用元論文 277 件、この内訳の 2.1%イラン: 引用元論文 259 件、この内訳の 2%オーストラリア: 引用元論文 254 件、この内訳の 1.9%日本: 引用元論文 212 件、この内訳の 1.6%カナダ: 引用元論文 202 件、この内訳の 1.5%
0%35.3%その他 23.9%

機関

分野

  • Medicine40.4%
  • Biochemistry, Genetics and Molecular Biology36.3%
  • Immunology and Microbiology9.8%
  • Agricultural and Biological Sciences4.7%
  • Engineering3.2%
  • Neuroscience1.9%
  • その他3.7%

トピック

  • Cancer Immunotherapy and Biomarkers6.3%
  • Insect Resistance and Genetics3.9%
  • Immunotherapy and Immune Responses3%
  • CAR-T cell therapy research3%
  • Immune cells in cancer2.8%
  • Cancer Cells and Metastasis2.3%
  • その他78.7%

共著者

全論文

検索で開く
  1. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

    著者: Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu - Molecular Cancer 2022 被引用: 1,452

  2. Notch signaling pathway: architecture, disease, and therapeutics

    著者: Binghan Zhou, Wanling Lin, Yaling Long, Yunkai Yang, Huan Zhang, Kongming Wu, Qian Chu - Signal Transduction and Targeted Therapy 2022 被引用: 1,052

  3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

    著者: Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo - Molecular Cancer 2019 被引用: 1,172

  4. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

    著者: Yuze Wu, Ming Yi, Mengke Niu, Qi Mei, Kongming Wu - Molecular Cancer 2022 被引用: 468

  5. Regulation of PD-L1 expression in the tumor microenvironment

    著者: Ming Yi, Mengke Niu, Linping Xu, Suxia Luo, Kongming Wu - Journal of Hematology & Oncology 2021 被引用: 672

  6. Recent advances in targeted strategies for triple-negative breast cancer

    著者: Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu - Journal of Hematology & Oncology 2023 被引用: 295

  7. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

    著者: Ming Yi, Dechao Jiao, Shuang Qin, Qian Chu, Kongming Wu, Anping Li - Molecular Cancer 2019 被引用: 611

  8. Targeting cytokine and chemokine signaling pathways for cancer therapy

    著者: Ming Yi, Tianye Li, Mengke Niu, Haoxiang Zhang, Yuze Wu, Kongming Wu, Zhijun Dai - Signal Transduction and Targeted Therapy 2024 被引用: 382

  9. Tumor organoids: applications in cancer modeling and potentials in precision medicine

    著者: Hanxiao Xu, Dechao Jiao, Aiguo Liu, Kongming Wu - Journal of Hematology & Oncology 2022 被引用: 260

  10. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

    著者: Anping Li, Ming Yi, Shuang Qin, Yongping Song, Qian Chu, Kongming Wu - Journal of Hematology & Oncology 2019 被引用: 436

  11. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

    著者: Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu - Molecular Cancer 2018 被引用: 793

  12. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

    著者: Yuheng Yan, Lan Huang, Yiming Liu, Ming Yi, Qian Chu, Dechao Jiao, Kongming Wu - Journal of Hematology & Oncology 2022 被引用: 205

  13. Targeting lysosomes in human disease: from basic research to clinical applications

    著者: Mengdie Cao, Xiangyuan Luo, Kongming Wu, Xingxing He - Signal Transduction and Targeted Therapy 2021 被引用: 213

  14. Exploiting innate immunity for cancer immunotherapy

    著者: Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai, Kongming Wu - Molecular Cancer 2023 被引用: 216

  15. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

    著者: Ming Yi, Mengke Niu, Yuze Wu, Hong Ge, Dechao Jiao, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Kongming Wu - Journal of Hematology & Oncology 2022 被引用: 178

  16. CD44 as a tumor biomarker and therapeutic target

    著者: Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu, Aiguo Liu - Experimental Hematology and Oncology 2020 被引用: 408

  17. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

    著者: Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu - Journal for ImmunoTherapy of Cancer 2022 被引用: 161

  18. The CXCL8-CXCR1/2 pathways in cancer

    著者: Qian Liu, Anping Li, Yijun Tian, Jennifer D. Wu, Yu Liu, Tengfei Li, Yuan Chen, Xinwei Han, Kongming Wu - Cytokine & Growth Factor Reviews 2016 被引用: 669

  19. Invasiveness, biology, ecology, and management of the fall armyworm, Spodoptera frugiperda

    著者: Marc Kenis, Giovanni Benelli, Antonio Biondi, Paul‐André Calatayud, Roger Day, Nicolas Desneux, Rhett D. Harrison, Darren J. Kriticos, Ivan Rwomushana, J. van den Berg, François Verheggen, Yongjun Zhang, Lakpo Koku Agboyi, Régis Besmer Ahissou, Malick N. Ba, Kongming Wu - Entomologia Generalis 2022 被引用: 366

  20. Organoid technology and applications in cancer research

    著者: Hanxiao Xu, Xiaodong Lyu, Ming Yi, Weiheng Zhao, Yongping Song, Kongming Wu - Journal of Hematology & Oncology 2018 被引用: 356

  21. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

    著者: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou, Kongming Wu - Journal of Hematology & Oncology 2021 被引用: 253

  22. EGFR-TKIs resistance via EGFR-independent signaling pathways

    著者: Qian Liu, Shengnan Yu, Weiheng Zhao, Shuang Qin, Qian Chu, Kongming Wu - Molecular Cancer 2018 被引用: 391

  23. Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis

    著者: Yu Jin, Yalin Kang, Minghuan Wang, Bili Wu, Beibei Su, Han Yin, Yang Tang, Qianxia Li, Wenjie Wei, Qi Mei, G. Hu, Veronika Lukacs‐Kornek, Jian Li, Kongming Wu, Xianglin Yuan, Wei Wang - Signal Transduction and Targeted Therapy 2022 被引用: 169

  24. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

    著者: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu, Kongming Wu - Journal of Hematology & Oncology 2021 被引用: 178